title: Clinical, biochemical and cytokinetic parameters for distinguishing smouldering and rapidly proliferating variants of acute leukaemia.
abstract: In a retrospective study, 10 patients with smouldering leukaemia (SML) were examined between 1982 and 1987. These patients typically showed the morphological criteria of acute myelogenous leukaemia (greater than 30% blasts in the bone marrow) in most cases together with a long survival time (median 16 months; 5 patients more than 22 months; 5 patients between 2.3 and 6.3 months) without the use of aggressive chemotherapy. At initial diagnosis the blast cell populations of patients with SML were characterized by significantly reduced cytosolic thymidine kinase activity (TK), thymidine-incorporation (dTR) and deoxyuridine incorporation (dUR) into DNA as well as reduced amounts of DNA-synthesizing S-phase-cells (%S) in the bone marrow (BM), compared to those patients with a rapidly proliferating acute myelogenous leukaemia (AML) and to healthy individuals. None of the SML-patients showed clinical symptoms such as night-sweat, weight-loss, hepato- and splenomegaly or lymphadenopathy at initial diagnosis. For characterization of SML vs AML we recommend the use of the biochemical parameter TK activity and the observed absence of the above-mentioned clinical symptoms. The transition to the rapidly proliferating type of AML can be recognized by an increase in the values of the biochemical and cytokinetic parameters. The blast count in the bone marrow is not suitable as a diagnostic criterion for the definition of SML vs AML or its transition to the rapidly proliferating type of AML.
authors.affiliation: Institut für Klinische Hämatologie, München, Fed. Rep. Germany.
authors.forename: V
authors.initials: V
authors.lastname: Nüssler
authors.forename: H
authors.initials: H
authors.lastname: Sauer
authors.forename: R
authors.initials: R
authors.lastname: Pelka-Fleischer
authors.forename: D
authors.initials: D
authors.lastname: Hölzel
authors.forename: W
authors.initials: W
authors.lastname: Wilmanns
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000754:Anemia, Refractory, with Excess of Blasts / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D001853:Bone Marrow / Q000473:pathology; D003561:Cytarabine / Q000627:therapeutic use; D004247:DNA / Q000096:biosynthesis; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013937:Thymidine Kinase / Q000378:metabolism
chemical_list: D003561:Cytarabine; D004247:DNA; D013937:Thymidine Kinase